Argenx
ARGX
#435
Rank
S$71.73 B
Marketcap
S$1,141
Share price
-0.55%
Change (1 day)
7.17%
Change (1 year)
Argenx is a Dutch company that develops antibody therapies to fight autoimmune diseases and cancer.

EPS for Argenx (ARGX)

EPS in 2026 (TTM): S$20.50

According to Argenx 's latest financial reports the company's current EPS (TTM) is S$20.20. In 2025 the company made an earnings per share (EPS) of S$26.93 an increase over its 2024 EPS that were of S$17.78.

EPS history for Argenx from 2011 to 2026

Annual EPS

Year EPS Change
2026 (TTM)S$20.50-23.87%
2025S$26.9351.44%
2024S$17.78-369.77%
2023S-$6.59-60.46%
2022S-$16.6763.33%
2021S-$10.21-40.37%
2020S-$17.12183.47%
2019S-$6.04123.09%
2018S-$2.7154.93%
2017S-$1.7514.07%
2016S-$1.5313.05%
2015S-$1.35-36.34%
2014S-$2.13209.04%
2013S-$0.69-33.99%
2012S-$1.04185.59%
2011S-$0.37